Uptal Patel

Uptal Patel has an extensive work experience in the field of medical research and academia. Uptal has held various roles and positions throughout their career. Starting in 2003, they served as a Robert Wood Johnson Clinical Scholar at the Department of Veterans Affairs. In 2005, they began their career at Duke University, initially as an Assistant Professor and later as an Associate Professor with tenure. During their time at Duke University, they gained broad research experience in nephrology, focusing on chronic kidney disease, end-stage renal disease, hypertension, and acute kidney injury. Uptal conducted research using various study types and methodologies, including surveys, qualitative analyses, systematic reviews, and clinical trials. Uptal also gained operational clinical trial experience.

In 2012, Patel joined NKDEP (National Kidney Disease Education Program) as a member and the founding chair of the Health Information Technology Working Group. Uptal remained in this position until present.

In 2016, Patel joined Gilead Sciences as an Executive Director of Clinical Research. Uptal led the global product clinical development for novel therapies for kidney diseases within the Inflammation and Respiratory Therapeutics Area. Uptal collaborated with various functional groups and fostered external collaborations to address the therapeutic needs of patients with kidney diseases.

In 2018, Patel became the Chair of the Board of Directors for the Kidney Health Initiative. Uptal also served as a member of the Board of Directors from 2018 to 2022.

In 2019, Patel became a Board Observer for Goldfinch Bio. Uptal held this role until 2021.

In 2021, Patel joined AstraZeneca as the Head of Clinical Renal and Executive Group Director for Early Cardiovascular, Renal, and Metabolism (CVRM). Uptal led the clinical development execution and strategy for a pipeline of novel therapies for various kidney diseases. Uptal collaborated with internal and external partners to overcome barriers and deliver new therapies for patients with kidney diseases.

In 2023, Patel is set to start a new position as the Chief Medical Officer at HI-Bio.

Throughout their career, Patel has been involved in numerous interdisciplinary projects and has received funding from various public and private sources, including the RWJ Foundation, VA, NIH, AHRQ, FDA, CMS, RPA, ASN, and commercial sponsors. Uptal has also made significant contributions to professional organizations like the American Society of Nephrology, where they served as the Chair of the Chronic Kidney Disease Advisory Group and as a member of the Board of Advisors.

Uptal Patel's education history begins in 1985 with their attendance at Webb School. However, no specific degree or field of study is provided for this period. From 1989 to 1993, Patel pursued a Bachelor of Arts (BA) degree in Chemistry/Biochemistry at UC San Diego. Following their undergraduate studies, Patel attended the University of California, San Francisco - School of Medicine from 1997 to 2001, where they obtained a Doctor of Medicine (MD) degree with a field of study in Medicine. In 2007, Patel began their doctoral studies in Epidemiology at the University of North Carolina at Chapel Hill. No end year is specified for this program, suggesting that Patel may still be pursuing their PhD.